CoChat

Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials

Vieta, Eduard, Locklear, Julie, Günther, Oliver, Ekman, Mattias, Miltenburger, Carolin, Chatterton, Mary Lou, Åström, Mikael, Paulsson, Björn · 2010 · Journal of Clinical Psychopharmacology
Cited by 119

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

This meta-analysis examined the effectiveness of treatments of bipolar depression. Trials were identified using the MEDLINE, EMBASE, http://www.clinicaltrials.gov, and Cochrane databases (1993 to July 2008). The outcome measures included mean change in Montgomery-Asberg Depression Rating Scale (MADRS) or Hamilton Depression Rating Scale (HAM-D) total scores, and rates of response and remission. Overall, 19 publications were included. Medications included quetiapine, lamotrigine, paroxetine, lithium, olanzapine, aripiprazole, phenelzine, and divalproex. The most trials were identified for quetiapine (5) and lamotrigine (6). Not all medications were associated with symptomatic improvement (significant reduction in MADRS/HAM-D total scores vs placebo), with lamotrigine, paroxetine, aripiprazole, and lithium not being different from placebo. Highest reductions in MADRS scores versus placebo were reported for the olanzapine-fluoxetine combination (1 trial: -6.6; 95% confidence interval [CI], -9.59 to -3.61; P = 0.000) and quetiapine monotherapy (5 trials: for 300 mg/d, -4.8; 95% CI, -6.18 to -3.49; P = 0.000; for 600 mg/d, -4.8; 95% CI, -6.22 to -3.28; P = 0.000), with quetiapine monotherapy also showing the highest reduction in HAM-D scores (4 trials: -4.0; 95% CI, -5.0 to -2.9; P = 0.000). All medications except paroxetine, lithium, aripiprazole, and phenelzine significantly improved the ratio of probabilities of response (overall rate, 1.31; 95% CI, 1.22-1.40) and remission (1.32; 95% CI, 1.20-1.45) versus placebo. Variability in efficacy exists between treatments of bipolar depression. Quetiapine and the olanzapine-fluoxetine combination showed the greatest symptomatic improvement. Efficacy considerations will need to be balanced against safety and tolerability of the individual agents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jcp.0b013e3181f15849

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 36

  1. Hirschfeld, 2005, Bipolar disorder-costs and comorbidity., Am J Manag Care, 11, S85
  2. Kasper, 2003, Issues in the treatment of bipolar disorder., Eur Neuropsychopharmacol, 13, S37, 10.1016/S0924-977X(03)00076-2 · DOI
  3. Oswald, 2007, Current issues in bipolar disorder: a critical review., Eur Neuropsychopharmacol, 17, 687, 10.1016/j.euroneuro.2007.03.006 · DOI
  4. Valtonen, 2008, Differences in incidence of suicide attempts during phases of bipolar I and II disorders., Bipolar Disord, 10, 588, 10.1111/j.1399-5618.2007.00553.x · DOI · Paper page
  5. 2002, Practice guideline for the treatment of patients with bipolar disorder (revision)., Am J Psychiatry, 159, 1
  6. Goodwin, 2003, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology., J Psychopharmacol, 17, 149, 10.1177/0269881103017002003 · DOI · Paper page
  7. Yatham, 2009, Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009., Bipolar Disord, 11, 225, 10.1111/j.1399-5618.2009.00672.x · DOI · Paper page
  8. Suppes, 2005, The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder., J Clin Psychiatry, 66, 870, 10.4088/JCP.v66n0710 · DOI · Paper page
  9. Vieta, 2008, Antidepressants in bipolar depression., Acta Psychiatr Scand, 118, 335, 10.1111/j.1600-0447.2008.01233.x · DOI · Paper page
  10. Suppes, 2010, Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression., J Affect Disord, 121, 106, 10.1016/j.jad.2009.10.007 · DOI
  11. Jensen, 2008, N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity., Neuropsychopharmacology, 33, 2303, 10.1038/sj.npp.1301646 · DOI · Paper page
  12. Yatham, 2005, Atypical antipsychotics in bipolar depression: potential mechanisms of action., J Clin Psychiatry, 66, 40
  13. Brugue, 2007, Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications., Prog Neuropsychopharmacol Biol Psychiatry, 31, 275, 10.1016/j.pnpbp.2006.06.014 · DOI · Paper page
  14. Calabrese, 2008, Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials., Bipolar Disord, 10, 323, 10.1111/j.1399-5618.2007.00500.x · DOI · Paper page
  15. van der Loos, 2009, Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial., J Clin Psychiatry, 70, 223, 10.4088/JCP.08m04152 · DOI · Paper page
  16. Gijsman, 2004, Antidepressants for bipolar depression: a systematic review of randomized, controlled trials., Am J Psychiatry, 161, 1537, 10.1176/appi.ajp.161.9.1537 · DOI · Paper page
  17. Gao, 2005, Typical and atypical antipsychotics in bipolar depression., J Clin Psychiatry, 66, 1376, 10.4088/JCP.v66n1106 · DOI
  18. Harel, 2008, Effectiveness and safety of adjunctive antidepressants in the treatment of bipolar depression: a review., Isr J Psychiatry Relat Sci, 45, 121
  19. Hamilton, 1960, A rating scale for depression., J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
  20. Montgomery, 1979, A new depression scale designed to be sensitive to change., Br J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  21. Frye, 2007, A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression., Am J Psychiatry, 164, 1242, 10.1176/appi.ajp.2007.06060981 · DOI · Paper page
  22. Vieta, 2002, A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers., J Clin Psychiatry, 63, 508, 10.4088/JCP.v63n0607 · DOI · Paper page
  23. Higgins, 2002, Quantifying heterogeneity in a meta-analysis., Stat Med, 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  24. Higgins, 2003, Measuring inconsistency in meta-analyses., BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  25. Agosti, 2007, Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression., Int Clin Psychopharmacol, 22, 309, 10.1097/YIC.0b013e3280c28410 · DOI
  26. Goldsmith, 2004, Spotlight on lamotrigine in bipolar disorder., CNS Drugs, 18, 63, 10.2165/00023210-200418010-00007 · DOI
  27. Nemeroff, 2001, Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression., Am J Psychiatry, 158, 906, 10.1176/appi.ajp.158.6.906 · DOI · Paper page
  28. Silverstone, 2001, Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial., Acta Psychiatr Scand, 104, 104, 10.1034/j.1600-0447.2001.00240.x · DOI · Paper page
  29. Goodnick, 2007, Bipolar depression: a review of randomised clinical trials., Expert Opin Pharmacother, 8, 13, 10.1517/14656566.8.1.13 · DOI
  30. Kemp, 2008, Bipolar depression: trial-based insights to guide patient care., Dialogues Clin Neurosci, 10, 181, 10.31887/DCNS.2008.10.2/dekemp · DOI
  31. Silverstone, 2004, A review of acute treatments for bipolar depression., Int Clin Psychopharmacol, 19, 113, 10.1097/00004850-200405000-00001 · DOI
  32. Perlis, 2006, Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial., J Clin Psychiatry, 67, 1747, 10.4088/JCP.v67n1112 · DOI · Paper page
  33. Martinez-Aran, 2008, Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change., Bipolar Disord, 10, 566, 10.1111/j.1399-5618.2008.00611.x · DOI
  34. Tohen, 2009, The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders., Bipolar Disord, 11, 453, 10.1111/j.1399-5618.2009.00726.x · DOI · Paper page
  35. Vieta, 2007, Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study., Bipolar Disord, 9, 413, 10.1111/j.1399-5618.2007.00479.x · DOI · Paper page
  36. Baptista, 2004, The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management., Metab Syndr Relat Disord, 2, 290, 10.1089/met.2004.2.290 · DOI · Paper page

Cited by

See all 119

Metadata

Authors
Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B.
Venue
Journal of Clinical Psychopharmacology
Published
2010-10
Volume
30
Issue
5
Pages
579-590
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2047612847
Cited by
119
References
16
FWCI
8.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. https://app.cochat.ai/papers/10.1097/jcp.0b013e3181f15849
The paper
Vieta, E., Locklear, J., Günther, O., Ekman, M., Miltenburger, C., Chatterton, M. L., Åström, M., & Paulsson, B. (2010). Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e3181f15849

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.